Eczema drug study halted early: what we learned about Long-Term safety

NCT ID NCT06447506

Terminated Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 09, 2026 · Updated 25 times

Summary

This study tested the long-term safety of an experimental drug called GSK1070806 in adults with moderate to severe atopic dermatitis (eczema). It was designed for people who had already completed an earlier study of the same drug. The study was terminated early, so only limited safety data was collected. The main goal was to track side effects, including serious infections and allergic reactions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Fountain Valley, California, 92708, United States
GSK Investigational Site

Pompano Beach, Florida, 33334, United States
GSK Investigational Site

Fayetteville, Georgia, 30214, United States
GSK Investigational Site

New York, New York, 10075, United States
GSK Investigational Site

Dublin, Ohio, 43016, United States
GSK Investigational Site

Santa Monica, Texas, 90404, United States
GSK Investigational Site

Buenos Aires, C1055AAO, Argentina
GSK Investigational Site

Buenos Aires, C1181ACH, Argentina
GSK Investigational Site

Ciudad Autonoma de Bueno, C1056ABI, Argentina
GSK Investigational Site

Córdoba, X5000AAW, Argentina
GSK Investigational Site

Rosario, S2002, Argentina
GSK Investigational Site

Pleven, 5800, Bulgaria
GSK Investigational Site

Sofia, 1510, Bulgaria
GSK Investigational Site

Barrie, Ontario, L4M 7G1, Canada
GSK Investigational Site

London, Ontario, N6H 5L5, Canada
GSK Investigational Site

Markham, Ontario, L3P1X2, Canada
GSK Investigational Site

Chongqing, 400016, China
GSK Investigational Site

Hangzhou, 310000, China
GSK Investigational Site

Shanghai, 200025, China
GSK Investigational Site

Shanghai, China
GSK Investigational Site

Prague, 10034, Czechia
GSK Investigational Site

Prague, Czechia
GSK Investigational Site

La Rochelle, 17019, France
GSK Investigational Site

Berlin, 10789, Germany
GSK Investigational Site

Münster, 48149, Germany
GSK Investigational Site

Athens, Greece
GSK Investigational Site

Chiba, 272-0033, Japan
GSK Investigational Site

Fukuoka, 807-8556, Japan
GSK Investigational Site

Fukuoka, 812-8582, Japan
GSK Investigational Site

Gunma, 370-0829, Japan
GSK Investigational Site

Hokkaido, 060-0033, Japan
GSK Investigational Site

Hokkaido, 080-0013, Japan
GSK Investigational Site

Kanagawa, 211-0063, Japan
GSK Investigational Site

Osaka, 583-8588, Japan
GSK Investigational Site

Osaka, 593-8324, Japan
GSK Investigational Site

Saitama, 343-8555, Japan
GSK Investigational Site

Chihuahua City, 31000, Mexico
GSK Investigational Site

Durango, 34000, Mexico
GSK Investigational Site

Guadalajara, 44628, Mexico
GSK Investigational Site

Panama City, 7099, Panama
GSK Investigational Site

Elblag, 82-300, Poland
GSK Investigational Site

Katowice, 40-600, Poland
GSK Investigational Site

Szczecin, 70-332, Poland
GSK Investigational Site

Ansan, 15355, South Korea
GSK Investigational Site

Seoul, 03722, South Korea
GSK Investigational Site

Seoul, 04763, South Korea
GSK Investigational Site

Seoul, 100 799, South Korea
GSK Investigational Site

Seoul, 150-950, South Korea
GSK Investigational Site

Córdoba, 14004, Spain
GSK Investigational Site

Granada, 18016, Spain
GSK Investigational Site

Vigo, 36206, Spain

Conditions

Explore the condition pages connected to this study.

DERMATITIS, ATOPIC